Your browser doesn't support javascript.
loading
Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials.
Choderlos de Laclos, Xavier; Risbourg, Séverine; Brennan, Bernadette; Bertucci, François; Gaspar, Nathalie; Gelderblom, Hans; Hawkins, Douglas S; Janeway, Katherine; Juergens, Heribert; Kasper, Bernd; Krailo, Mark D; Cécile Le Deley, Marie; Marec-Bérard, Perrine; McCabe, Martin G; Metzler, Markus; Ranft, Andreas; Strauss, Sandra; Tabone, Marie-Dominique; Windsor, Rachael; Dirksen, Uta; Gandemer, Virginie.
Afiliação
  • Choderlos de Laclos X; Oncology Department, Eugène Marquis Centre, Avenue de la Bataille Flandres-Dunkerque, Rennes, France. Electronic address: x.choderlos-de-laclos@rennes.unicancer.fr.
  • Risbourg S; Methodology and Biostatistics Unit, Oscar Lambret Centre, 3 Rue Frédéric Combemale, Lille, France. Electronic address: s-risbourg@o-lambret.fr.
  • Brennan B; Department of paediatric oncology, Royal Manchester Children's Hospital, Manchester, UK. Electronic address: Bernadette.Brennan@mft.nhs.uk.
  • Bertucci F; Department of Medical Oncology, Paoli-Calmettes Institute, Aix-Marseille Université, 232 Boulevard de Sainte-Marguerite, Marseille, France. Electronic address: BERTUCCIF@ipc.unicancer.fr.
  • Gaspar N; Department of Oncology for Child and adolescent, Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, France. Electronic address: Nathalie.GASPAR@gustaveroussy.fr.
  • Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, The Netherlands. Electronic address: a.j.gelderblom@lumc.nl.
  • Hawkins DS; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA. Electronic address: doug.hawkins@seattlechildrens.org.
  • Janeway K; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA. Electronic address: Katherine_Janeway@dfci.harvard.edu.
  • Juergens H; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Germany, West German Cancer Centre (WTZ) Network, Muenster, Germany. Electronic address: jurgh@ukmuenster.de.
  • Kasper B; University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC), Sarcoma Unit, Mannheim, Germany. Electronic address: Bernd.Kasper@medma.uni-heidelberg.de.
  • Krailo MD; University of Southern California, Los Angeles, CA, USA. Electronic address: mkrailo@childrensoncologygroup.org.
  • Cécile Le Deley M; Methodology and Biostatistics Unit, Oscar Lambret Centre, 3 Rue Frédéric Combemale, Lille, France. Electronic address: m-ledeley@o-lambret.fr.
  • Marec-Bérard P; Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, 28 Prom. Léa et Napoléon Bullukian, Lyon, France. Electronic address: perrine.marec-berard@ihope.fr.
  • McCabe MG; Division of Cancer Sciences, University of Manchester & The Christie NHS Foundation Trust, Manchester, UK. Electronic address: Martin.McCabe@manchester.ac.uk.
  • Metzler M; Department of Pediatrics, University Hospital Erlangen, and NCT WERA, Erlangen, Germany. Electronic address: Markus.Metzler@uk-erlangen.de.
  • Ranft A; Pediatrics III, University Hospital Essen, Essen, Germany, West German Cancer Centre (WTZ), German Consortium for Translational Cancer Research (DKTK), and National Center for Tumordiseases site Essen, Essen, Germany. Electronic address: Andreas.ranft@uk-essen.de.
  • Strauss S; London Sarcoma Service, UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: sandra.strauss@nhs.net.
  • Tabone MD; Pediatric Hematology and Oncology Department, Armand Trousseau Hospital, AP-HP, Sorbonne University, 26 avenue du Docteur Arnold-Netter, Paris, France. Electronic address: marie-dominique.tabone@aphp.fr.
  • Windsor R; London Sarcoma Service, UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: rachael.windsor@nhs.net.
  • Dirksen U; Pediatrics III, University Hospital Essen, Essen, Germany, West German Cancer Centre (WTZ), German Consortium for Translational Cancer Research (DKTK), and National Center for Tumordiseases site Essen, Essen, Germany. Electronic address: Uta.Dirksen@uk-essen.de.
  • Gandemer V; Department of Pediatric Onco-hematology, University Hospital, 16 Bd de Bulgarie, Rennes, France. Electronic address: virginie.gandemer@chu-rennes.fr.
Eur J Cancer ; 208: 114229, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39032218
ABSTRACT

INTRODUCTION:

Ewing sarcoma (ES), is a rare cancer affecting children, adolescents and adults. After VIDE (vincristine-ifosfamide-doxorobucin-etoposide) induction chemotherapy, Busulfan-Melphalan (BuMel) high-dose chemotherapy followed by autologous hematopoietic stem cells transplantation improved outcomes in unfavourable localized ES, but with more toxicities than conventional chemotherapy (VAI Vincristine-dactinomycin-Ifosfamide). We evaluated whether the risk of acute toxicity associated with BuMel compared to VAI varied according to age in patients recruited in the R2Loc and R2Pulm randomised trials of the Euro-E.W.I.N.G.99 and Ewing-2008 trials.

METHODS:

We included patients with a localized high-risk disease, or pulmonary or pleural metastasis. We analysed the risk of severe toxicity according to randomised treatment group (VAI versus BuMel) and age group (<12 years, 12-17 years, 18-24 years, ≥25 years). We evaluated the heterogeneity of treatment effects by age group using interaction terms in logistic multivariable models.

RESULTS:

The analysis included 243 patients treated with VAI and 205 with BuMel. Overall, BuMel was associated with a higher risk of severe acute toxicity than VAI particularly haematological, gastrointestinal, liver, sinusoidal occlusive syndrome, and infections. Severe haematological toxicity and lower general condition were significantly more frequent in younger patients, whatever treatment. We did not observe any significant heterogeneity in terms of the excess risk of severe toxicities associated with BuMel compared to VAI according to age group.

CONCLUSION:

The excess of acute toxicity associated with BuMel compared to VAI does not vary significantly with age, suggesting the feasibility of BuMel across all age groups.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Transplante Autólogo / Bussulfano / Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Melfalan Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Eur J Cancer Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Transplante Autólogo / Bussulfano / Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Melfalan Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Eur J Cancer Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido